Recent Posts
- MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline
- EMIH response to the European Commission call for evidence on the EU Biotech Act
- The “Microbiome Times Forum” brought together key experts to shape the future of microbiome innovation in the European Union
- The European Microbiome Innovation for Health Association Welcomes 13 New Members, Strengthening Europe’s Leadership in Microbiome Innovation
- MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease
Recent Comments
No comments to show.